OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

trialsTrialRecruiting

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

A phase 3 trial of Anlotinib, Penpulimab in hepatocellular carcinoma, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.